Assertio Therapeutics Ownership
| ASRT Stock | USD 0.72 0.01 1.41% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 95 M | Current Value 95 M | Avarage Shares Outstanding 28 M | Quarterly Volatility 23.9 M |
Assertio |
Assertio Stock Ownership Analysis
About 30.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.57. Some equities with similar Price to Book (P/B) outperform the market in the long run. Assertio Therapeutics has Price/Earnings To Growth (PEG) ratio of 1.5. The entity recorded a loss per share of 0.23. The firm had not issued any dividends in recent years. Assertio Therapeutics had 1:4 split on the 18th of May 2021. Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois. Assertio Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. For more info on Assertio Therapeutics please contact Brendan OGrady at 224 419 7106 or go to https://www.assertiotx.com.Besides selling stocks to institutional investors, Assertio Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Assertio Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Assertio Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Assertio Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Assertio Therapeutics are currently held by insiders. Unlike Assertio Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Assertio Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Assertio Therapeutics' insider trades
Assertio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Assertio Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Assertio Therapeutics backward and forwards among themselves. Assertio Therapeutics' institutional investor refers to the entity that pools money to purchase Assertio Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 459.7 K | Bridgeway Capital Management, Llc | 2024-12-31 | 455.3 K | Empowered Funds, Llc | 455.3 K | Acadian Asset Management Llc | 2024-12-31 | 424.1 K | Cm Management, Llc | 400 K | Perritt Capital Management Inc. | 2024-12-31 | 372.9 K | State Street Corp | 2024-12-31 | 366.9 K | Squarepoint Ops Llc | 2024-12-31 | 232.2 K | Northern Trust Corp | 2024-12-31 | 227.2 K | Nantahala Capital Management, Llc | 2024-12-31 | 8.1 M | Vanguard Group Inc | 2024-12-31 | 4.4 M |
Assertio Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Assertio Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Assertio Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Assertio Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Assertio Therapeutics Outstanding Bonds
Assertio Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Assertio Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Assertio bonds can be classified according to their maturity, which is the date when Assertio Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.